Erratum to Studies on abacavir-induced hypersensitivity reaction: A successful example of translation of pharmacogenetics to personalized medicine (SCIENCE CHINA Life Sciences, (2013), 56, 2 (119-124), 10.1007/s11427-013-4438-8);Studies on abacavir-induced hypersensitivity reaction: A successful example of translation of pharmacogenetics to personalized medicine

Science China Life Sciences

Volumn 56, Issue 2, 2013, Pages 119-124

  Guo, YongLi ^a   Shi, LeMing ^a   Hong, HuiXiao ^a   Su, ZhenQiang ^a   Fuscoe, James ^a   Ning, BaiTang ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

abacavir; drug safety; HLA B*57:01; HLA B*57:01 screening; hypersensitivity reaction (HSR); personalized medicine; pharmacogenetics

Indexed keywords

EID: 84873705190     PISSN: 16747305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11427-013-4456-6     Document Type: Erratum

References (55)

1. Foster R H, Faulds D. Abacavir. Drugs, 1998, 55: 729-736.
2. Hervey P S, Perry C M. Abacavir: a review of its clinical potential in patients with HIV infection. Drugs, 2000, 60: 447-479.
3. Hughes A R, Spreen WR, Mosteller M, et al. Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility. Pharmacogenomics J, 2008, 8: 365-374.
4. Chaponda M, Pirmohamed M. Hypersensitivity reactions to HIV therapy. Br J Clin Pharmacol, 2011, 71: 659-671.
5. Hughes C A, Foisy M M, Dewhurst N, et al. Abacavir hypersensitivity reaction: an update. Ann Pharmacother, 2008, 42: 387-396.
6. Clay P G. The abacavir hypersensitivity reaction: a review. Clin Ther, 2002, 24: 1502-1514.
7. Hetherington S, McGuirk S, Powell G, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther, 2001, 23: 1603-1614.
8. Rodriguez-Novoa S, Soriano V. Current trends in screening across ethnicities for hypersensitivity to abacavir. Pharmacogenomics, 2008, 9: 1531-1541.
9. Symonds W, Cutrell A, Edwards M, et al. Risk factor analysis of hypersensitivity reactions to abacavir. Clin Ther, 2002, 24: 565-573.
10. Cutrell A G, Hernandez J E, Fleming J W, et al. Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir. Ann Pharmacother, 2004, 38: 2171-2172.
11. Peyrieere H, Nicolas J, Siffert M, et al. Hypersensitivity related to abacavir in two members of a family. Ann Pharmacother, 2001, 35: 1291-1292.
12. Hetherington S, Hughes A R, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet, 2002, 359: 1121-1122.
13. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet, 2002, 359: 727-732.
14. Arrizabalaga J, Rodriguez-Alcantara F, Castaner J L, et al. Prevalence of HLA-B*5701 in HIV-infected patients in Spain (results of the EPI Study). HIV Clin Trials, 2009, 10: 48-51.
15. Berka N, Gill J M, Liacini A, et al. Human leukocyte antigen (HLA) and pharmacogenetics: screening for HLA-B*57: 01 among human immunodeficiency virus-positive patients from southern Alberta. Hum Immunol, 2012, 73: 164-167.
16. Cao K, Hollenbach J, Shi X, et al. Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations. Hum Immunol, 2001, 62: 1009-1030.
17. Hughes A R, Mosteller M, Bansal A T, et al. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics, 2004, 5: 203-211.
18. Hughes D A, Vilar F J, Ward C C, et al. Pirmohamed M, Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics, 2004, 14: 335-342.
19. Lee K W, Oh D H, Lee C, et al. Allelic and haplotypic diversity of HLA-A, -B, -C, -DRB1, and -DQB1 genes in the Korean population. Tissue Antigens, 2005, 65: 437-447.
20. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med, 2008, 358: 568-579.
21. Martin A M, Nolan D, Gaudieri S, et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci USA, 2004, 101: 4180-4185.
22. Middleton D, Hawkins B R, Williams F, et al. HLA class I allele distribution of a Hong Kong Chinese population based on high-resolution PCR-SSOP typing. Tissue Antigens, 2004, 63: 555-561.
23. Middleton D, Menchaca L, Rood H, et al. New allele frequency database: http://www. allelefrequencies. net. Tissue Antigens, 2003, 61: 403-407.
24. Moore C B, John M, James I R, et al. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science, 2002, 296: 1439-1443.
25. Munderi P, Snowden W B, Walker A S, et al. Distribution of HLA-B alleles in a Ugandan HIV-infected adult population: NORA pharmacogenetic substudy of DART. Trop Med Int Health, 2011, 16: 200-204.
26. Nolan D, Gaudieri S, Mallal S. Pharmacogenetics: a practical role in predicting antiretroviral drug toxicity? J HIV Ther, 2003, 8: 36-41.
27. Park W B, Choe P G, Song K H, et al. Should HLA-B*5701 screening be performed in every ethnic group before starting abacavir? Clin Infect Dis, 2009, 48: 365-367.
28. Phillips E, Mallal S. Successful translation of pharmacogenetics into the clinic: the abacavir example. Mol Diagn Ther, 2009, 13: 1-9.
29. Phillips E J. Genetic screening to prevent abacavir hypersensitivity reaction: are we there yet? Clin Infect Dis, 2006, 43: 103-105.
30. Rauch A, Nolan D, Martin A, et al. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis, 2006, 43: 99-102.
31. Saito S, Ota S, Yamada E, et al. Allele frequencies and haplotypic associations defined by allelic DNA typing at HLA class I and class II loci in the Japanese population. Tissue Antigens, 2000, 56: 522-529.
32. Sun H Y, Hung C C, Lin P H, et al. Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected patients in Taiwan. J Antimicrob Chemother, 2007, 60: 599-604.
33. Saag M, Balu R, Phillips E, et al. High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis, 2008, 46: 1111-1118.
34. Martin S, Weltzien H U. T cell recognition of haptens, a molecular view. Int Arch Allergy Immunol, 1994, 104: 10-16.
35. Lavergne S N, Park B K, Naisbitt D J. The roles of drug metabolism in the pathogenesis of T-cell-mediated drug hypersensitivity. Curr Opin Allergy Clin Immunol, 2008, 8: 299-307.
36. Pichler W J. Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept. Curr Opin Allergy Clin Immunol, 2002, 2: 301-305.
37. Pichler W J, Beeler A, Keller M, et al. Pharmacological interaction of drugs with immune receptors: the p-i concept. Allergol Int, 2006, 55: 17-25.
38. Pirmohamed M, Naisbitt D J, Gordon F, et al. The danger hypothesis-potential role in idiosyncratic drug reactions. Toxicology, 2002, 181-182: 55-63.
39. Li J, Uetrecht J P. The danger hypothesis applied to idiosyncratic drug reactions. Handb Exp Pharmacol, 2010, 196: 493-509.
40. + T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity, 2008, 28: 822-832.
41. Yang L, Chen J, He L. Harvesting candidate genes responsible for serious adverse drug reactions from a chemical-protein interactome. PLoS Comput Biol, 2009, 5: e1000441.
42. Illing P, Vivian J, Dudek N, et al. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature, 2012, 486: 554-558.
43. Ostrov D, Grant B, Pompeu Y, et al. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proc Natl Acad Sci USA, 2012.
44. Zucman D, Truchis P, Majerholc C, et al. Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population. J Acquir Immune Defic Syndr, 2007, 45: 1-3.
45. Nolan D. HLA-B*5701 screening prior to abacavir prescription: clinical and laboratory aspects. Crit Rev Clin Lab Sci, 2009, 46: 153-165.
46. Dervieux T, Bala M V. Overview of the pharmacoeconomics of pharmacogenetics. Pharmacogenomics, 2006, 7: 1175-1184.
47. Rodriguez-Novoa S, Garcia-Gasco P, Blanco F, et al. Value of the HLA-B*5701 allele to predict abacavir hypersensitivity in Spaniards. AIDS Res Hum Retroviruses, 2007, 23: 1374-1376.
48. Schackman B R, Scott C A, Walensky R P, et al. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS, 2008, 22: 2025-2033.
49. Lalonde R G, Thomas R, Rachlis A, et al. Successful implementation of a national HLA-B*5701 genetic testing service in Canada. Tissue Antigens, 2010, 75: 12-18.
50. Nieves Calatrava D, Calle-Martin Ode L, Iribarren-Loyarte J A, et al. Cost-effectiveness analysis of HLA-B*5701 typing in the prevention of hypersensitivity to abacavir in HIV+ patients in Spain. Enferm Infecc Microbiol Clin, 2010, 28: 590-595.
51. Phillips E J, Wong G A, Kaul R, et al. Clinical and immunogenetic correlates of abacavir hypersensitivity. AIDS, 2005, 19: 979-981.
52. Shear N H, Milpied B, Bruynzeel D P, et al. A review of drug patch testing and implications for HIV clinicians. AIDS, 2008, 22: 999-1007.
53. Phillips E J, Sullivan J R, Knowles S R, et al. Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir. AIDS, 2002, 16: 2223-2225.
54. Su Z, Ning B, Fang H, et al. Next-generation sequencing and its applications in molecular diagnostics. Expert Rev Mol Diagn, 2011, 11: 333-343.
55. ten Bosch J R, Grody W W. Keeping up with the next generation: massively parallel sequencing in clinical diagnostics. J Mol Diagn, 2008, 10: 484-492.